BioCentury
ARTICLE | Financial News

CRO Viva could get $749M valuation in Hong Kong listing, Ascentage refiles

April 26, 2019 8:07 PM UTC

Viva would raise HK$1.4 billion ($172.2 million) and be valued at HK$5.9 billion ($748.7 million) if the drug discovery services company prices its Hong Kong IPO at the midpoint of the range it proposed April 25.

Viva Biotech Holdings (Shanghai, China) said it will sell 345 million shares at HK$3.42-HK$4.41 on the Hong Kong stock exchange. The company proposed the listing in July 2018 (see "CRO Viva Biotech Proposes HKEX Listing")...